# Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

> **NCT00485966** · PHASE2 · WITHDRAWN · sponsor: **Cylene Pharmaceuticals** · enrollment: 25 (estimated)

## Conditions studied

- B-Cell Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** CX-3543

## Key facts

- **NCT ID:** NCT00485966
- **Lead sponsor:** Cylene Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-06
- **Primary completion:** —
- **Final completion:** 2008-06
- **Target enrollment:** 25 (ESTIMATED)
- **Why stopped:** This study was withdrawn prior to patient enrollment
- **Last updated:** 2008-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00485966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00485966, "Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00485966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*